The concept that the disruption of the balance between TGFβ tumor suppressor activity and the survivin/XIAP cell stress response enables metastatic colonization of distant organs raises the concern that therapies aimed at inhibition of TGFβ signaling may be deleterious to at least a subset of cancer patients. Here, BIRC5 is linked to cancer.